Edda Spiekerkoetter is a Respiratory physician. OpenAlex indexes 134 publications with 4,945 citations (h-index 35); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Drive, Rm H3143a
Stanford University Department Of Medicine, Pccm
Stanford, CA 943055236
Telephone
650-723-6381Registry record last updated 25 Aug 2009.
Clinical trials
- FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Sponsor: Edda Spiekerkoetter
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20259 payments
- Sunovion Pharmaceuticals Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
50.5%Endothelin Receptor Antagonist27.6%Ambrisentan63%Opsumit21%Letairis16%Part D<11 patientsLoop diuretic11.8%Furosemide57%Bumetanide43%Part D<11 patients+ 2 more classes in this area
Genitourinary & hormones
39.4%Phosphodiesterase 5 Inhibitor39.4%Sildenafil Citrate64%Tadalafil36%Part D<11 patientsMetabolism & gastrointestinal
6.1%Potassium supplement6.1%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2011–2025 per NIH RePORTER. The latest:
- Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regression
Stanford University
FY2025$702,732R01HL169787 - Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regression
Stanford University
FY2024$688,595R01HL169787 - Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs
Stanford University
FY2024$401,078R01HL158868
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Somatic mutations in arteriovenous malformations in hereditary hemorrhagic telangiectasia support a bi-allelic two-hit mutation mechanism of pathogenesis
The American Journal of Human Genetics
2024 - Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target
Frontiers in Cardiovascular Medicine
2022 - The Human Respiratory Microbiome: Current Understandings and Future Directions
American Journal of Respiratory Cell and Molecular Biology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”